Breaking News

BMS, Syngene Expand Research Pact in India

June 3, 2014

Will encompass a broader range of integrated service offerings

Bristol-Myers Squibb and Syngene International, India’s largest CRO, have extended their drug discovery and development collaboration in India for another five years. Financial terms were not disclosed.
BMS has been working with Syngene and its parent company, Biocon, since 2007, to develop integrated capabilities in medicinal and process chemistry, biology, biotechnology, biomarkers, drug metabolism and pharmacokinetics, analytical research, and pharmaceutical development, at BMS’ Research Center (BBRC) in Bangalore.
To date, the collaboration has produced six drug candidates for development and has reduced BMS’ costs associated with advancing new compounds to first-in-human studies.
Peter Bains, director, Syngene International, said, “We are extremely delighted to extend our discovery and development partnership with BMS. This extension reflects the strength of our existing collaboration, which has delivered many successful outcomes. The scope of Syngene’s engagement has expanded to encompass a broad range of integrated service offerings across the drug discovery and development continuum. We remain committed to supporting Bristol-Myers Squibb in their pursuit of developing new and innovative medicines for the future.”
Francis Cuss, executive vice president and chief scientific officer, Bristol-Myers Squibb, said, “I am excited about the opportunity to continue our highly productive collaboration with Biocon and Syngene. The BBRC has supported the nonclinical development of a large proportion of our small-molecule portfolio assets since its inception, and is a premier example of the high-quality innovative drug hunting that is taking place in India today.”

Related Contract Manufacturing:

blog comments powered by Disqus
  • FDA & Drug Development

    FDA & Drug Development

    Rachelle Du2019Souza, Regulatory Heights Inc.||September 8, 2016
    You must perform the necessary due diligence to stay on top of regulatory developments

  • The Role of Alliances in Modern Drug Development

    The Role of Alliances in Modern Drug Development

    Dr. Claire Madden-Smith, Senior Vice President, Juniper Pharma Services||September 8, 2016
    Combining expertise to get drug candidates through development

  • Limiting APIs in Manufacturing Effluent

    Limiting APIs in Manufacturing Effluent

    Joan Tell, Robert Drinane, Bruce Naumann, Jessica Vestel, and Gregory Gagliano, Merck & Co., Inc.||June 2, 2016
    An approach for setting limits on pharmaceuticals discharged in manufacturing effluent